Trade

with

Repligen Corp
(NASDAQ: RGEN)
AdChoices
23.93
+0.84
+3.64%
After Hours :
-
-
-

Open

23.48

Previous Close

23.09

Volume (Avg)

249.41k (384.90k)

Day's Range

23.15-24.38

52Wk Range

9.97-24.68

Market Cap.

753.84M

Dividend Rate ( Yield )

-

Beta

1.23

Shares Outstanding

32.65M

P/E Ratio (EPS)

46.51 (0.50)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 68.17M

    • Net Income

    • 16.09M

    • Market Cap.

    • 753.84M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 24.69

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.23

    • Forward P/E

    • -

    • Price/Sales

    • 11.29

    • Price/Book Value

    • 6.42

    • Price/Cash flow

    • 31.25

      • EBITDA

      • 26.18M

      • Return on Capital %

      • 13.97

      • Return on Equity %

      • 15.69

      • Return on Assets %

      • 13.97

      • Book Value/Share

      • 3.54

      • Shares Outstanding

      • 32.65M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -11.20

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • 13.70

          • 17.04

          • Net Income

            Q/Q (last year)

          • -37.80

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 24.52

          • 63.43

          • Net Income

            5-Year Annual Average

          • -13.50

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 62.54

            • 82.75

            • Pre-Tax Margin

            • 33.29

            • 39.38

            • Net Profit Margin

            • 24.69

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 8.38

              • 2.92

              • Quick Ratio

              • 6.74

              • 2.35

              • Interest Coverage

              • 434.22

              • 38.02

              • Leverage Ratio

              • 1.12

              • 2.21

              • Book Value/Share

              • 3.54

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 45.66

                • 277.78

                • P/E Ratio 5-Year High

                • 49.65

                • 634.30

                • P/E Ratio 5-Year Low

                • 5.83

                • 124.82

                • Price/Sales Ratio

                • 11.29

                • 9.35

                • Price/Book Value

                • 6.42

                • 8.50

                • Price/Cash Flow Ratio

                • 31.25

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 15.69

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 13.97

                    (-)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 15.73

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 140.67k

                  • 117.08k

                  • Inventory Turnover

                  • 2.12

                  • 1.48

                  • Asset Turnover

                  • 0.57

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  22.87M
                  Operating Margin
                  33.55
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  31.25
                  Ownership

                  Institutional Ownership

                  88.11%

                  Top 10 Institutions

                  37.98%

                  Mutual Fund Ownership

                  49.53%

                  Float

                  86.22%

                  5% / Insider Ownership

                  7.20%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,273,961

                  • 0.00

                  • 3.90

                  • SPDR® S&P Biotech ETF

                  •  

                    947,856

                  • 0.00

                  • 3.31

                  • iShares Core S&P Small-Cap (AU)

                  •  

                    617,446

                  • 0.24

                  • 2.16

                  • PowerShares Dynamic Biotech&Genome Port

                  •  

                    577,129

                  • 0.00

                  • 2.02

                  • Conestoga Small Cap

                  •  

                    566,300

                  • 0.00

                  • 1.73

                  • Vanguard Total Stock Mkt Idx

                  •  

                    500,954

                  • 0.00

                  • 1.53

                  • Federated Kaufmann Fund

                  •  

                    500,000

                  • 0.00

                  • 1.53

                  • iShares Russell 2000 (AU)

                  •  

                    494,086

                  • -0.90

                  • 1.73

                  • Fidelity® Small Cap Growth Fund

                  •  

                    490,000

                  • -57.02

                  • 1.50

                  • Columbia Small Cap Core Fund

                  •  

                    456,903

                  • 0.00

                  • 1.40

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    2,103,241

                  • +86.63%

                  • 6.44

                  • BlackRock Fund Advisors

                  •  

                    2,039,225

                  • +59.52%

                  • 6.24

                  • Dimensional Fund Advisors, Inc.

                  •  

                    1,341,581

                  • +6.94%

                  • 4.11

                  • State Street Corp

                  •  

                    1,271,098

                  • -23.84%

                  • 3.89

                  • Acadian Asset Management LLC

                  •  

                    1,262,271

                  • -1.86%

                  • 3.87

                  • Vanguard Group, Inc.

                  •  

                    1,113,605

                  • +24.70%

                  • 3.41

                  • Columbia Mangmt Investment Advisers, LLC

                  •  

                    1,004,840

                  • +29.94%

                  • 3.08

                  • Wall Street Associates Llc

                  •  

                    734,900

                  • +0.53%

                  • 2.25

                  • Renaissance Technologies Corp

                  •  

                    707,200

                  • +51.76%

                  • 2.17

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Aggressive Growth

                  Style

                  Small Growth

                  Repligen Corp was incorporated in May 1981, under the laws of the State of Delaware. The Company is a life sciences company that develops, manufactures and markets consumable bioprocessing products for life sciences companies and bio...morepharmaceutical manufacturing companies. It is also engaged in the manufacture of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. The Company also supplies growth factor products used to increase cell culture productivity during the biomanufacturing process. In the burgeoning area of biomanufacturing technologies, it has developed and currently markets a series of OPUS or Open-Platform, User-Specified chromatography columns for use in clinical-scale manufactur...moreing. The Company manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sell its chromatography columns, as well as media and quality test kits, directly to biopharmaceutical companies or contract manufacturing organizations. It manufactures seven forms of commercial scale Protein A including native Protein A for life sciences companies under long-term supply agreements which expire between 2016 and 2021. On December 28, 2012, it out-licensed its SMA program, led by RG3039, to Pfizer Inc. On January 21, 2014, it also out-licensed its histone deacetylase inhibitor portfolio which includes the Friedreich’s ataxia program, to BioMarin Pharmaceuticals Inc., or BioMarin. The Company has developed RG1068, a synthetic human hormone for the improved detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and potentially other pancreatic diseases. It conducts manufacturing in Waltham and at its facility in Lund, Sweden. It sells its bioprocessing products through direct sales force to partners such as GE Healthcare, EMD Millipore, Sigma Aldrich and to distributors in certain foreign markets.lessless

                  Key People

                  Dr. Walter C. Herlihy,PhD

                  CEO/Chief Accounting Officer/Director/President/Treasurer

                  Mr. Karen A. Dawes

                  Chairman of the Board/Director

                  ProfessorDr. Alexander Rich,M.D.

                  Chairman Emeritus/Co-Founder

                  Mr. Jon K. Snodgres

                  CFO

                  Howard Benjamin,PhD

                  Vice President, Divisional

                  • Repligen Corp

                  • 41 Seyon Street, Building 1

                  • Waltham, MA 02453

                  • USA.Map

                  • Phone: +1 781 250-0111

                  • Fax: +1 781 250-0115

                  • repligen.com

                  Incorporated

                  1981

                  Employees

                  116

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: